BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. Aliment Pharmacol Ther. 2004;20 Suppl 6:11-19. [PMID: 15496214 DOI: 10.1111/j.1365-2036.2004.02161.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2006;23:281-287. [PMID: 16393308 DOI: 10.1111/j.1365-2036.2006.02756.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
2 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 15.7] [Reference Citation Analysis]
3 Ma TK, Lam Y, Tan VP, Kiernan TJ, Yan BP. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacology & Therapeutics 2010;125:249-59. [DOI: 10.1016/j.pharmthera.2009.10.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
4 Dadabhai A, Friedenberg FK. Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opin Drug Saf 2009;8:119-26. [PMID: 19236223 DOI: 10.1517/14740330802622892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
5 El-halabi MM, Zgheib N, Mansour NM, Malli A, Ghaith OA, Mahfouz R, Alam S, Sharara AI. CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Antiplatelet Action of Clopidogrel: . Journal of Cardiovascular Pharmacology 2013;62:41-9. [DOI: 10.1097/fjc.0b013e31828ecf44] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
6 Tang C, Chen Z, Dai X, Zhu W, Zhong D, Chen X. Mechanism of Reductive Metabolism and Chiral Inversion of Proton Pump Inhibitors. Drug Metab Dispos 2019;47:657-64. [PMID: 30962289 DOI: 10.1124/dmd.118.086090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Srinivas NR. Letter: CYP2C19 polymorphisms and exacerbation of rabeprazole's effects on celecoxib-induced small bowel injury. Aliment Pharmacol Ther 2017;46:706-7. [PMID: 28880446 DOI: 10.1111/apt.14240] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Kinoshita Y, Kato M, Fujishiro M, Masuyama H, Nakata R, Abe H, Kumagai S, Fukushima Y, Okubo Y, Hojo S, Kusano M. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. J Gastroenterol 2018;53:834-44. [PMID: 29188387 DOI: 10.1007/s00535-017-1417-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Aung AK, Haas DW, Hulgan T, Phillips EJ. Pharmacogenomics of antimicrobial agents. Pharmacogenomics 2014;15:1903-30. [PMID: 25495412 DOI: 10.2217/pgs.14.147] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
10 Bang CS, Shin WG, Seo SI, Choi MH, Jang HJ, Park SW, Kae SH, Yang YJ, Shin SP, Baik GH, Kim HY. Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study. Surg Endosc 2019;33:1376-85. [PMID: 30167954 DOI: 10.1007/s00464-018-6412-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Boj-carceller D. Proton pump inhibitors: impact on glucose metabolism. Endocrine 2013;43:22-32. [DOI: 10.1007/s12020-012-9755-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
12 Tran M, Tafreshi J, Pai RG. Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians. J Cardiovasc Pharmacol Ther 2010;15:326-37. [DOI: 10.1177/1074248410369109] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
13 Kinoshita Y, Kusano M, Iwakiri K, Fujishiro M, Tachikawa N, Haruma K. Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study. Curr Ther Res Clin Exp 2018;88:26-34. [PMID: 30038671 DOI: 10.1016/j.curtheres.2018.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ. 2006;70:101. [PMID: 17149430 DOI: 10.5688/aj7005101] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
15 Kinoshita Y, Ashida K, Hongo M; Japan Rabeprazole Study Group for NERD. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2011;33:213-224. [PMID: 21083596 DOI: 10.1111/j.1365-2036.2010.04508.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
16 Qiao H, Hu Y, Tian X, Jia L, Gao N, Zhang L, Guo Y. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 2006;62:107-12. [DOI: 10.1007/s00228-005-0063-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
17 Wang HS, Oh DS, Anderson A, Nieto J, Tien P, Ohning G, Pisegna JR. Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity. Gut Liver 2008;2:30-8. [PMID: 20485608 DOI: 10.5009/gnl.2008.2.1.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Chen H, Li X, Ge Z, Gao Y, Chen X, Cui Y. Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy. Can J Gastroenterol 2010;24:197-201. [PMID: 20352149 DOI: 10.1155/2010/846353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
19 Huang B, Huang Y, Li Y, Yao H, Jing X, Huang H, Li J. Adverse Cardiovascular Effects of Concomitant Use of Proton Pump Inhibitors and Clopidogrel in Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis. Archives of Medical Research 2012;43:212-24. [DOI: 10.1016/j.arcmed.2012.04.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
20 Wang Y, Zhang H, Meng L, Wang M, Yuan H, Ou N, Zhang H, Li Z, Shi R. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur J Clin Pharmacol 2010;66:563-9. [PMID: 20414645 DOI: 10.1007/s00228-010-0821-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
21 Varannes SBD, Sacher-Huvelin S, Vavasseur F, Masliah C, Rhun ML, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting. World J Gastroenterol 2006; 12(16): 2569-2573 [PMID: 16688803 DOI: 10.3748/wjg.v12.i16.2569] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
22 Lin SF, Lin PC, Chang CC, Chang WL, Chu FY. Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay. Medicine (Baltimore) 2020;99:e23695. [PMID: 33327360 DOI: 10.1097/MD.0000000000023695] [Reference Citation Analysis]
23 Ghoshal UC, Chourasia D. Genetic factors in the pathogenesis of gastroesophageal reflux disease. Indian J Gastroenterol. 2011;30:55-62. [PMID: 21562717 DOI: 10.1007/s12664-011-0095-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
24 Zhang L, Mei Q, Li QS, Hu YM, Xu JM. The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people: CYP2C19 and IL-1 genotypes in H. pylori cure rate. Journal of Clinical Pharmacy and Therapeutics 2010;35:713-22. [DOI: 10.1111/j.1365-2710.2009.01140.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
25 Ji CR, Liu J, Li YY, Qiao C, Qu JY, Hu JN, Lin MJ, Ji R, Li LX, Zuo XL, Li YQ. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. J Dig Dis 2020;21:549-57. [PMID: 32833285 DOI: 10.1111/1751-2980.12934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008;13:532-541. [PMID: 19166419 DOI: 10.1111/j.1523-5378.2008.00643.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 6.7] [Reference Citation Analysis]
27 Giannini EG, Savarino V, Testa R. Monitoring Cytochrome P-450 Activity During Rabeprazole Treatment in Patients with Gastresophageal Reflux Disease. Dig Dis Sci 2006;51:1602-6. [DOI: 10.1007/s10620-005-9035-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Tang C, Li L, Ma X, Wang J, Chen B, Dai X, Zhang Y, Chen X. Qualitative and quantitative determination of anaprazole and its major metabolites in human plasma. J Pharm Biomed Anal 2020;183:113146. [PMID: 32086126 DOI: 10.1016/j.jpba.2020.113146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers: COMBINED ANALYSIS OF RABEPRAZOLE VS. ESOMEPRAZOLE ON INTRAGASTRIC pH. Alimentary Pharmacology & Therapeutics 2007;25:501-10. [DOI: 10.1111/j.1365-2036.2006.03221.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
30 Belhocine K, Vavasseur F, Volteau C, Flet L, Touchefeu Y, Bruley des Varannes S. Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. BMC Gastroenterol. 2014;14:128. [PMID: 25027286 DOI: 10.1186/1471-230X-14-128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Maiti R, Jaida J, Israel PL, Koyagura N, Mukkisa S, Palani A. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safety. J Pharmacol Pharmacother 2011;2:150-7. [PMID: 21897706 DOI: 10.4103/0976-500X.83278] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Arévalo-Galvis A, Otero-Regino WA, Ovalle-Celis GN, Rodríguez-Gómez ER, Trespalacios-Rangel AA. Prevalence of CYP2C19 polymorphism in Bogotá, Colombia: The first report of allele *17. PLoS One 2021;16:e0245401. [PMID: 33503046 DOI: 10.1371/journal.pone.0245401] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tseng P, Lee Y, Chiu H, Wang H, Lin J, Wu M. A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes. Journal of Clinical Gastroenterology 2009;43:920-5. [DOI: 10.1097/mcg.0b013e3181960628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
34 Shao F, Sun J, Wang G, Xie H, Zhu X, Zhang J. Liquid chromatographic–mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats. Biopharm Drug Dispos 2007;28:177-86. [DOI: 10.1002/bdd.543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
35 Cho H, Choi MK, Cho DY, Yeo CW, Jeong HE, Shon JH, Lee JY, Shin JS, Cho M, Kim DY. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J Clin Pharmacol. 2012;52:976-984. [PMID: 21593280 DOI: 10.1177/0091270011408611] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
36 Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur J Clin Pharmacol 2006;62:685-91. [PMID: 16850327 DOI: 10.1007/s00228-006-0148-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
37 Ait-Mokhtar O, Bonello L, Benamara S, Paganelli F. High on treatment platelet reactivity. Heart Lung Circ 2012;21:12-21. [PMID: 22000771 DOI: 10.1016/j.hlc.2011.08.069] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
38 Klotz U. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs). Eur J Clin Pharmacol 2009;65:1-2. [DOI: 10.1007/s00228-008-0571-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
39 Çelik F, Aypak C, Özdemir A, Görpelioğlu S. Inappropriate Prescribing of Proton Pump Inhibitors in Outpatient Clinics. Gastroenterol Nurs 2021;44:84-91. [PMID: 33795619 DOI: 10.1097/SGA.0000000000000500] [Reference Citation Analysis]
40 Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors - focus on pKa and metabolism. Aliment Pharmacol Ther Symp Series 2006;2:340-50. [DOI: 10.1111/j.1746-6342.2006.00065.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
41 Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009;43:1266-1274. [PMID: 19470853 DOI: 10.1345/aph.1m051] [Cited by in Crossref: 67] [Cited by in F6Publishing: 17] [Article Influence: 5.6] [Reference Citation Analysis]
42 Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin Gastroenterol. 2006;40:515-520. [PMID: 16825934 DOI: 10.1097/00004836-200607000-00010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
43 Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: A meta-analysis. Am J Gastroenterol. 2006;101:1467-1475. [PMID: 16863547 DOI: 10.1111/j.1572-0241.2006.00717.x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 96] [Article Influence: 7.1] [Reference Citation Analysis]
44 El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447-460. [PMID: 29620484 DOI: 10.1080/17425255.2018.1461835] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
45 Yamano HO, Matsushita HO, Yanagiwara S. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. J Gastroenterol Hepatol 2008;23:534-40. [PMID: 17725594 DOI: 10.1111/j.1440-1746.2007.05104.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]